What the FDA labels say about taking them together
Canakinumab and warfarin
Canakinumab's FDA label of June 8, 2026 names warfarin in its drug interactions section; the warfarin label PlainMeds reads does not name canakinumab. The canakinumab label: “This is clinically relevant for CYP450 substrates with a narrow therapeutic index, where the dose is individually adjusted (e.g., warfarin).”
Check it at the source: the canakinumab FDA label on DailyMed (effective June 8, 2026, Novartis Pharmaceuticals Corporation); the warfarin FDA label on DailyMed (effective May 29, 2026, Amneal Pharmaceuticals LLC).
What does the canakinumab label say about warfarin?
Canakinumab label, drug interactionsThis is clinically relevant for CYP450 substrates with a narrow therapeutic index, where the dose is individually adjusted (e.g., warfarin).
Source: FDA drug label (Ilaris), Novartis Pharmaceuticals Corporation, effective June 8, 2026 (SPL set 7d271f3b-e4f9-4d80-8dcf-28d49123f80e), via openFDA; the full label on DailyMed
What does the warfarin label say about canakinumab?
Warfarin's label (effective May 29, 2026) does not name canakinumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Warfarin Sodium), Amneal Pharmaceuticals LLC, effective May 29, 2026 (SPL set 558b7a0d-5490-4c1b-802e-3ab3f1efe760), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Canakinumab | Warfarin | |
|---|---|---|
| Labeled for | Gout | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.093 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once